Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease Nov 4, 2026
Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML Nov 4, 2026
Actinium Pharmaceuticals Announces Acceptance of ATNM-400 Abstract for Presentation at SABCS 2026 Highlighting Activity Across Therapy-Resistant Breast Cancer Models Nov 2, 2026
Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026 Oct 23, 2026
Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer Oct 20, 2026
Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models Oct 20, 2026
Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026 Oct 19, 2026
Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models Oct 16, 2026
